cabozantinib
exelixis
['atlantis', 'urothelial']
atlantis was the first uk study to treat advanced urothelial cancer with molecularly targeted maintenance therapy. prof robert jones from shares final analysis from this innovative #crukfunded #clinicaltrial today at 20:45bst #asco22: 
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK